Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection

NCT ID: NCT06018363

Last Updated: 2025-08-19

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-06-01
• Study Completion Date: 2027-12-31

Brief Summary

B7-H3 is expressed at low levels in normal tissues but overexpressed in various tumor tissues. The ubiquitous expression of B7-H3 in tumors of different grades is a key feature for brain gliomas. The immunohistochemistry study showed that B7-H3 is abundantly expressed on both glioma (especially high-grade glioma) cells and tumor-associated endothelial cells. For GBM, the expression of B7-H3 is intensely positive, especially on tumor cells and vascular endothelial cells, which makes B7-H3 a potential immunotherapeutic target.

γδ T cells recognize tumor cells without being restricted by MHC molecules, and thus can be used in allogeneic therapy without the risk of causing graft-versus-host disease.

This study is an open-label, single-arm, dose-escalation and dose-expansion clinical study aimed at evaluating the safety and efficacy of allogeneic B7-H3 CAR γδT in patients with malignant glioma.

Conditions

Brain Gliomas; High-Grade Gliomas; GBM

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Patients with R/R HGG

Group Type: EXPERIMENTAL

Allogenic B7-H3 CAR-γδT cell(QH104)

Intervention Type: BIOLOGICAL

Dose escalation (3+3) : dose 1 (1 × 10^7 CAR+cells) , dose 2 (3 × 10^7 CAR+cells), dose 3 (6× 10^7 CAR+cells), once every 4 weeks via an Ommaya reservoir or intrathecal administration.

Dose expansion 1: dose of RP2D, once every 4 weeks via an Ommaya reservoir or intrathecal administration.

Dose expansion 2: 3 × 10^7 CAR+cells, every two weeks for three consecutive months, then changed to once every 4 weeks via an Ommaya reservoir or intrathecal administration.

Interventions

Allogenic B7-H3 CAR-γδT cell(QH104)

Dose escalation (3+3) : dose 1 (1 × 10^7 CAR+cells) , dose 2 (3 × 10^7 CAR+cells), dose 3 (6× 10^7 CAR+cells), once every 4 weeks via an Ommaya reservoir or intrathecal administration.

Dose expansion 1: dose of RP2D, once every 4 weeks via an Ommaya reservoir or intrathecal administration.

Dose expansion 2: 3 × 10^7 CAR+cells, every two weeks for three consecutive months, then changed to once every 4 weeks via an Ommaya reservoir or intrathecal administration.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• 1)Age 18-70 years old (both ends included), both male and female;
• 2)At least one evaluable lesion, with previous biopsy or histopathological confirmation of high-grade glioma (WHO grade 3-4), and after comprehensive treatment, imaging examination indicates continued progression or recurrence;
• 3) The pathological tissues removed by surgery can be used for immunohistochemical detection of target proteins (paraffin sections should be within half a year), and the expression of B7-H3 is positive;
• 4) KPS ≥ 60 points;
• 5)Expected survival > 3 months;
• 6)Substantially normal bone marrow reserve function and normal liver and renal function (laboratory tests need to be fulfilled before receiving QH104 Cell Injection for the first time):White blood cell count (WBC) ≥ 3 x 10^9/L;Lymphocyte count (LY) ≥ 0.8 x 10^9/L;Hemoglobin (Hb) ≥ 90g/L;Platelet (PLT) ≥80×10^9/L;Albumin transaminase (ALT) & albumin transaminase (AST) <1.5×ULN;Serum creatinine (Cr) <1.5 x ULN;Total bilirubin < 1.5 x ULN;PT & PTT ≤ 1.25 x ULN.
• 7)No obvious hereditary diseases;
• 8)Normal cardiac function with cardiac ejection index >55%;
• 9)No bleeding and coagulation disorders;
• 10)Women of childbearing age (15-49 years old) must have had a pregnancy test with a negative result within 7 days prior to the start of treatment, and subjects are willing to use contraception during the clinical trial and for 3 months after the last cell infusion;
• 11) Sign the informed consent form.

Exclusion Criteria

• 1)Pregnant and lactating women;
• 2)Those with organ failure:Heart: Class III and IV;Liver: up to grade C of the Child-Turcotte Liver -Function Classification;Kidney: chronic kidney disease stage 4 or above; renal insufficiency stage III or above;Lungs: symptoms of severe respiratory failure with involvement of other organs;Brain: central nervous system abnormalities or impaired consciousness;
• 3)patients with combined second tumors;
• 4)patients with active hepatitis B or C virus, HIV infection, or other untreated active infection;
• 5)any severe, uncontrolled systemic autoimmune disease or any unstable systemic disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, Crohn's disease, and temporal arteritis;
• 6)Current systemic use of steroid cell (except for recent or current use of inhaled steroids) substances;
• 7) have a chronic disease requiring immunologic or hormonal therapy;
• 8) have an allergy to immunotherapy and related cells;
• 9) 10)Patients with a history of organ transplantation or who are awaiting organ transplantation;
• 10)Participation in other clinical trials within the previous 30 days;
• 11)Those who are not suitable for clinical trials for other reasons in the opinion of the investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Dushu Lake Hospital Affiliated to Soochow University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Dushu Lake Hospital Affiliated to Soochow University

Suzhou, Jiangsu, China

Site Status: RECRUITING

Countries

China

Facility Contacts

Yulun Huang

Role: primary

huangyulun@suda.edu.cn

+86 130 1388 9432

Xuetao Li

Role: backup

lixuetao0405@126.com

+86 151 9563 7789

Other Identifiers

QH10401-GC-01（0）

Identifier Type: -

Identifier Source: org_study_id